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QUESTIONS AND ANSWERS ABOUT TOLBUTAMIDE,
THE ORAL HYPOGLYCEMIC AGENT
FRED W .

WHITEHOUSE, M . D . '

AND JOHN

B . BRYAN,

M.D.*

When insulin was f o u n d to be ineffective by m o u i h . attention was given to the
deyelopmenl o f an orally etfective hypoglycemic agent.

Manv compounds

have heen

lesled over the years. M o s l have been too toxic f o r clinical use.
Janbon in 1S)42 first described the hvpoghcemic action o f sulfonamide compounds,'
Recenlly. m o d i f i e d preparations

have been siudied intensively in Germany

and

Ihe

United .States. Onc preparalion. carbutamide. proved lo be loo toxic f o r general clinical
use.

T o l b u t a m i d e ^ a closely related cunipound. has proven to be relatively safe and

has been made available throughout this country f o r Ihe ireatmeni of diabetes mellitus.
T h i s report summarizes our experience w i t h Ihis agent and allempis to c l a r i f y
quesiions thai have arisen w i t h ils use.
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and
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reader
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Queslion:
Answer:

What is tolbutamide?
I l is a sullonykirca conipound Ihal has a significani hvpoglycemic aclion

when taken b\ m o u t h .
Queslion:
,\nsuer;

H o « ' does lolbutamide acl?
( urrenl opinions suggesi mulliphasic activity. Insulin musl be present

l o r an e f l e c l . Fxperimcnlal evidence indicates thi;I lolbutamide I I 1 causes cither a prodiiciion of or a release o f insulin f r o m ibe beta cells o f the pancreas. ( 2 ) inhibils antiinsulin faclors (insulinase) in the liver. i S ) slows ihe release o f glucose f r o m the liver,
l o l b u i . i m i d e has no e f f e c i on olher endocrine
uptake b\ the individual cell.
i l u i i u d or adrenal glands.

organs nor does it increase glucose

Ils action is not inhibiled by ablalion o f the p i t u i t a r \ ,

There is no toxic e f f e c i on the alpha cells of ihe pancreas.

It must be emphasi/ed that the linal and possibh correcl modus operandi o f tolbutamide
li.i-^ no! \ e l been esl.iblished.
Question:
.Answer:
no

Is Ihere a h \ p o g l \ c e m i c effeci in all diabetics as is true w i t h insulin?
No,

h\pogIycemic

Animals f o l l o w i n g lotal pancreatectomy
effeci.

I n humans the

or alloxanizalion show

percenlage o f patients w i t h

a significani

h \ p o g h c e m i c effect closely parallels the percenlage of patients w i l h insulin extractable
f r o m the

pancreas.

Those palienis without extractable

insulin do

noi

respond

lo

tolbutamide.
Queslion:

Is tolbutamide effecliye in diabeiic acidosis?

.Answer: N o Neither is i l effeclive in other acule complicalions o f diabetes,
inc'udint; inleclions and surgical stress.
•Division of Metabolism.
Onnasc R — Upjohn Co.nipany. Kalaiiia/oo, Michigan

Whilehouse

and

Bryan

Question: What arc the indications and conlra-indications for ils use?
Answer: Table 1 indicates our curreni opinion based on over a year's clinical
i^xpericnce. These indications are generallv irue, allhough there may be exceptions,
rhey are lo be used as a guide when applied to the individual patient.

Indications
Diabetes less than 10 years' duration.
( Inset of diabetes over age 40.
•.dull type diabetes.
Diabetes controlled with /ov ihan 30 uniis of
insulin daily.
I oupcraiive palienl.

Contra-ind icat ions
Diabetes over 10 years' duralion,
Onsel under age 40.
Juvenile type diabetes.
Diabetes controlled wilh imuf than 30 unils of
insulin daily.
Uncooperative paticni.
Acute complications.
(Cetosis.

Ihe presence of one conlra-indicalion is sufficient lo disqualify a palienl for
i 'Ihutamide Iherapy. Tolbutamide is an insulin subsiiuite clinically. Il is not indicated
in the obese diabeiic palient before an adequate trial wilh undernutrition has been
.ecomplished. Onlv if weight loss does not occur, or if not successful in conlrollini^
Ihe diabetes, should lolbuUimide be consideretl.
Queslion: Whal are the side-effects of tolbutamide?
Answer: We have seen one case of dermalilis and one case of nauseii and
omiling, requiring cessation of the drug, in l.'^O cases treated with lolbutamide. There
may be transient leukopenia, but no olher hemalologic complications have been encountered. Crystalluria does not occur. We have exjierienced no hepatic dysfunction.
("t'Donovan' reporls three perceni side-effects in over 70[)il clinic:il cases. These have
all been mild. There are no known dealhs diicctlv allribulable to lolbutamide.
Queslion: How is a patieni regulaled wiih tolbutamide?
Answer: Once a decision to use tolbutamide is made, inilialion may be accomplished either in the hospital or with frequent office visits. Hospitalizalion is recommended if there is any queslion regarding lhc palienl's likelihood of response. The
following program has been generally adopled in our clinic:
1. Begin wiih I gram 3 times daily.
2. After 1-3 days, decrease to 1 gram twice daily.
3. Adjust the dailv maintenance dosage with the help of frequent urine lesls
and blood tests for" sugar.
4. If the patieni is on insulin al the lime of initiation,
a. omit insulin if less than 20 unils per day.
b. If over 20 units daily, decrease Ihe daily dose 25-50 perceni initially, and
then eliminate ihe insulin if Ihe blood sugars so indicale.
5. Check the white blood count Irequenlly al the beginning of therapy.

Tolbutamide
Question,

How long should one await a successful response?

Answer: Not longer than 7-10 days. If the degree of diabetic control deteriorates
sooner, abandon the trial at once and start insulin, The development of ketonuria
indicates failure. It is imperative thai the patieni be kept under close observation
during Ihis trial period.
Queslion: Whal is the average maintenance dose?
Answer: Table 2 records the maintenance dosage of 83 patients regulaled on
lolbulamide.
Table 2
Maintenance Dosage of Tolbutamide
Grams per day
0.5
1.0
1.5
2.0
3.0

Number of patients
8
23
14
24
14

Question: Can tolbutamide and insulin be used logelher?
Answer: Yes, but there is little point in it. The only advantage of lolbulamide
over insulin is its effectiveness hy mouth. Theoretically, one might lower a very large
daily dose of insulin to a more convenient level wilh the aid of lolbutamide. We have
tried this twice wiihout success.
Question: Should lolbulamide he used in the obese diahetic patieni?
Answer; Tolbutamide, like insulin, is contra-indicated initially in the obese
diabeiic patieni. Undernutrition should be tried first. If optimum weight is accomplished and still the diabetes is not controlled, then tolbutamide may be tried. If poor
cooperalion prevents weight loss, then lolbutamide probably should also be avoided.
Queslion: Can the diet be liberalized when lolbulamide is used?
Answer: No, If anything, it should be followed more closely.
Queslion: Once on tolbutamide, must the palienl stay on it?
Answer: Like insulin, no. A patient wilh mild diabetes and good control may
improve his glucose tolerance lo the degree lhat diet alone will adequately control
his diabetes.
Question: If the patieni is regulated on tolbutamide, will insulin again be necessary?
Answer: Most patients on lolbulamide will require insulin if acute stress occurs.
A few patients well regulated on tolbutamide at the beginning will gradually lose this
cood control. They must restart insulin.
Queslion: How is tolbutamide supplied?
Answer: Half-gram tablets, hollies of 50. S6.75 per bottle, filled by prescription
only.
ISI
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Queslion: Docs lolbutamide have any antibacterial activity?
Answer: No.
Question: Has hypoglycemia been a problem?
Answer: No, Wc have seen no serious hypoglycemic reactions. There have been
several mild reactions occurring during the first few days following initiation of
i.ilbutamide therapy.
Question: Whal have been the failures?
Answer: Our failures with the use of lolbulamide include patients wilh diabetes
LUid carcinoma of ihe pancreas (4 cases), sieroid diabetes ( I case) and juvenile type
diabetes. The basic nature of tbc diabetes appears lo be the most importani determinanl
III the individual response to tolbutamide.
Queslion: What theoretical danger exists wilh the use of lolbulamide?
Answer: Permanent diabetes can be produced in animals by chronic overstimulalion of the beta cells of the pancreas. Tolbutamide is a beta cell stimulator. Will
lolbulamide in time produce "total" diabetes in patients mainlained on il?
A palient with diabetes well regulaled with lolbutamide will lose this sensitivity
in the presence of acule complicalions. This may make ihe palient more vulnerable
lo the rapid occurrence of ketosis and acidosis Ihan a similar patient regulaled with
insulin.
Summary:
The experience at the Henry Ford Hospital with tolbutamide is reviewed. Perlinenl
questions regarding ils use are answered. The only advantage of tolbutamide over
insulin is onc of convenience — il is effective orally. The present and future heallh
of the diabetic must not be compromised for mere convenience. Thc patients using
tolbutamide musl be carefully and thoughlfully selected.
We are grateful lo Doctor C. J. O'Donovan of the Upjohn Company, Kalam.izoo, for the
generous supply of lolbulamide.
BIBLIOGRAPHY
1. Janbon, M . . La/erges, P,, and Melropolilanski, J. H,: Elude du meiabolismc du sulfa-iso
propyl-ihiodiazol IVK. 57ou 2.254 Rl*l che?, le sujet sain ei en cours dc iraitemcnt. Comporiemeni
de la glyccmie. Monipellier med, 21-21:489, 1942.
2. Symposium on insulin, glucagon and the oral hypoglycemic agenis, Diabelcs 6: No. 3,
May-June. 1957.
3. Symposium on clinical and experimenlal effects of sulfonylureas in diabetes mellilus.
Metabolism 5: No. 6, Part 2, Nov. 1956.
4. The effecis of the sulfonylureas and related compounds
diabetes. Ann, New York Acad. Sci. 71: Art. 1. July 10, 1957.
5. O'Donovan. C. J.: Personal communication.

in experimental

and clinical

